Physician profile
Mark A Lewis
NPI 1538262670
$4,986.38
in general payments reported to CMS, 2019-2025
21 companies · $30.01 in 2025
The $30.01 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $246 · 2021: $585 · 2022: $895 · 2023: $1,207 · 2024: $908 · 2025: $30.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847 · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.28 |
| Education | $297.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,527.57 | 2019-2024 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $789.33 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $676.03 | 2019-2024 | |
| Lilly USA, LLC | $313.17 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Pfizer INC. | $310.04 | 2021-2024 | |
| Sun Pharmaceutical Industries INC. | $284.35 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Genzyme Corporation | $257.77 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $216.59 | 2022-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $101.33 | 2019-2024 | Libtayo |
| Amgen INC. | $94.18 | 2022-2024 | Otezla |
| Leo Pharma INC. | $84.44 | 2019-2022 | |
| Almirall LLC | $61.75 | 2019 | |
| Incyte Corporation | $52.33 | 2021-2024 | Opzelura |
| Genentech USA, INC. | $40.58 | 2019 | |
| Arcutis Biotherapeutics, INC. | $35.60 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $35.32 | 2019 | |
| Sandoz INC. | $26.56 | 2024 | |
| Ucb, INC. | $25.71 | 2019-2024 | Bimzelx |
| Dermira, INC. | $23.97 | 2019 | |
| Merck Sharp & Dohme LLC | $17.16 | 2019 | |
| Vyne Pharmaceuticals INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.